-
Published10/01/2025
-
Today14/02/2025
-
Deadline04/01/2027
-
Opening of tenders04/01/2027
Utilities
- indicates text translated automatically in your browsing language
Drug discount agreements from 01.03.2025 on various active ingredients in the context of an open-house procedure Text automatically translated in your browsing language Automatically translated
The subject of this publication is the conclusion of contracts pursuant to § 130a(8) SGB V for several active substances in the context of a so-called open-house procedure: Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of discount agreements pursuant to § 130a(8) SGB V for the following active substances: Cetirizine (R06AE07) Epinephrine (C01CA24) Formoterol & Glycopyrronium Bromide (R03AL07) Fusidic Acid (D06AX01, S01AA13) Lipegfilgrastim (L03AA14) Macrogol Combinations (A06AD65) Methoxy-Polyethylenglycol-Epoetin beta (B03XA03) Octreotide (H01CB02) Pyridostigmine (N07AA02) Tiotropium & Olodaterol (R03AL06) On this basis, the contract term is a maximum of 24 months. Text automatically translated in your browsing language Automatically translated
sen-info
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.